{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:44:17Z","timestamp":1790142257920,"version":"4.0.1"},"reference-count":63,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020643","name":"MRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Biomedical Research Centre Funding Scheme"},{"name":"NIHR\/Imperial Clinical Research Facility"},{"DOI":"10.13039\/100030827","name":"NHS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022513","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022513","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Post-Doctoral Fellowship"},{"name":")"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Androgen abuse is an increasing public health concern, particularly among young men seeking muscular or image enhancement. Although most achieve biochemical recovery within 12 months of cessation, mood disturbances, sexual dysfunction, and fatigue are widely reported for years afterward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine symptom severity the relationship to biochemical recovery during the first year after androgen abuse cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study of community-dwelling men grouped as nonusers, current users, or past users who had ceased within the last 12 months. Participants completed questionnaires on androgen and substance use and 4 validated instruments assessing mood (Beck Depression Inventory-II), anxiety (Generalized Anxiety Disorder-7), sexual function (International Index of Erectile Function-15), and quality-of-life (36-item Short Form). Morning fasted serum hormonal analysis and screening to exclude undisclosed androgen use were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred forty-seven men were included: 50 nonusers, 125 current users, and 72 past users. Self-reported psychiatric diagnoses were 2.5-fold higher among current and past users than nonusers. Total testosterone (TT) was highest in current users (P &amp;lt; .001) with no difference between past and nonusers. Past users reported significantly worse mood, anxiety, sexual function, and quality of life vs nonusers. Multivariable analyses showed psychiatric comorbidity was independently associated with depression (P = .001), anxiety (P &amp;lt; .001), and poorer quality-of-life (P &amp;lt; .05). Older age and higher luteinizing hormone were associated with reduced sexual function (P &amp;lt; .05), while lower testosterone showed only a modest association with depressive symptoms (P = .03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among men in the first year after stopping androgen abuse, psychological symptoms and reduced quality-of-life were most strongly associated with psychiatric comorbidity than biochemical recovery. These findings challenge the assumption that androgen withdrawal symptoms are predominantly driven by hypogonadism and supports developing psychological and behavioral interventions, rather than pharmacological, to support androgen withdrawal in men.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag110","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:49:41Z","timestamp":1773233381000},"page":"2649-2663","source":"Crossref","is-referenced-by-count":3,"title":["Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1121-9211","authenticated-orcid":false,"given":"Bonnie","family":"Grant","sequence":"first","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kean","sequence":"additional","affiliation":[{"name":"BloodWorks Ltd , Bradford BD17 5RT ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-3659","authenticated-orcid":false,"given":"Nipun Lakshitha","family":"de Silva","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London , London W12 0NN ,","place":["UK"]},{"name":"Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University , Ratmalana 10370 ,","place":["Sri Lanka"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Drug Control Centre, King's Forensics, Faculty of Life Science and Medicine, King's College London , London SE1 9NH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver C B","family":"Quinton","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Gumssani","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-4563","authenticated-orcid":false,"given":"Paul","family":"Bassett","sequence":"additional","affiliation":[{"name":"Statsconsultancy Ltd , Bucks HP7 9EN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5950-4316","authenticated-orcid":false,"given":"Waljit S","family":"Dhillo","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-3453","authenticated-orcid":false,"given":"Anne","family":"Lingford-Hughes","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Department of Brain Sciences, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-4720","authenticated-orcid":false,"given":"Kim","family":"Wolff","sequence":"additional","affiliation":[{"name":"Drug Control Centre, King's Forensics, Faculty of Life Science and Medicine, King's College London , London SE1 9NH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-8223","authenticated-orcid":false,"given":"Channa N","family":"Jayasena","sequence":"additional","affiliation":[{"name":"Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"1","key":"2026081219562927000_dgag110-B1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40798-021-00371-1","article-title":"Social media, body image and resistance training: creating the perfect \u2018me\u2019 with dietary supplements, anabolic steroids and SARM's","volume":"7","author":"Hilkens","year":"2021","journal-title":"Sports Med Open"},{"key":"2026081219562927000_dgag110-B2","doi-asserted-by":"crossref","first-page":"152602","DOI":"10.1016\/j.comppsych.2025.152602","article-title":"Mapping the pathway to anabolic-androgenic steroids (AAS) use","volume":"141","author":"Laskowski","year":"2025","journal-title":"Compr Psychiatry"},{"issue":"5","key":"2026081219562927000_dgag110-B3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","article-title":"The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis","volume":"24","author":"Sagoe","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"6","key":"2026081219562927000_dgag110-B4","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1210\/clinem\/dgz324","article-title":"Rate and extent of recovery from reproductive and cardiac dysfunction due to androgen abuse in men","volume":"105","author":"Shankara-Narayana","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081219562927000_dgag110-B5","doi-asserted-by":"crossref","first-page":"e14372","DOI":"10.1111\/and.14372","article-title":"Prospective study on blood pressure, lipid metabolism and erythrocytosis during and after androgen abuse","volume":"54","author":"Smit","year":"2022","journal-title":"Andrologia"},{"key":"2026081219562927000_dgag110-B6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.mehy.2016.06.004","article-title":"Anabolic androgenic steroid-induced hepatotoxicity","volume":"93","author":"Bond","year":"2016","journal-title":"Med Hypotheses"},{"issue":"3","key":"2026081219562927000_dgag110-B7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/joim.12850","article-title":"Health consequences of androgenic anabolic steroid use","volume":"285","author":"Horwitz","year":"2019","journal-title":"J Intern Med"},{"issue":"12","key":"2026081219562927000_dgag110-B8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/da.23287","article-title":"Psychiatric morbidity among men using anabolic steroids","volume":"39","author":"Windfeld-Mathiasen","year":"2022","journal-title":"Depress Anxiety"},{"key":"2026081219562927000_dgag110-B9","author":"Department of Health & Social Care"},{"issue":"Suppl 1","key":"2026081219562927000_dgag110-B10","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jsxm.2022.01.106","article-title":"94 Anabolic-androgenic steroid use is associated with Major depressive disorder and suicide attempt: analysis of a multi-national database","volume":"19","author":"Nackeeran","year":"2022","journal-title":"J Sex Med"},{"key":"2026081219562927000_dgag110-B11","author":"Centre for Social Justice"},{"issue":"4","key":"2026081219562927000_dgag110-B12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/humrep\/deaa366","article-title":"Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study","volume":"36","author":"Smit","year":"2021","journal-title":"Hum Reprod"},{"issue":"8","key":"2026081219562927000_dgag110-B13","doi-asserted-by":"crossref","first-page":"e0161208","DOI":"10.1371\/journal.pone.0161208","article-title":"Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study","volume":"11","author":"Rasmussen","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"2026081219562927000_dgag110-B14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/add.12850","article-title":"Prolonged hypogonadism in males following withdrawal from anabolic\u2013androgenic steroids: an under-recognized problem","volume":"110","author":"Kanayama","year":"2015","journal-title":"Addiction"},{"issue":"6","key":"2026081219562927000_dgag110-B15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ejendo\/lvad164","article-title":"Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study","volume":"189","author":"Grant","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026081219562927000_dgag110-B16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13011-023-00573-8","article-title":"The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men","volume":"18","author":"Grant","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"2026081219562927000_dgag110-B17","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1210\/clinem\/dgad551","article-title":"Persistently decreased quality of life and its determinants in previous illicit androgen users","volume":"109","author":"Bulut","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081219562927000_dgag110-B18","doi-asserted-by":"crossref","first-page":"2337717","DOI":"10.1080\/07853890.2024.2337717","article-title":"Anabolic-androgenic steroids are linked to depression and anxiety in male bodybuilders: the hidden psychogenic side of anabolic androgenic steroids","volume":"56","author":"Karagun","year":"2024","journal-title":"Ann Med"},{"issue":"1","key":"2026081219562927000_dgag110-B19","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1210\/clinem\/dgad475","article-title":"Predictors of ongoing androgen abuse. A prospective 2-year follow up of 100 male androgen abusers","volume":"109","author":"Smit","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081219562927000_dgag110-B20","doi-asserted-by":"crossref","first-page":"75\u2013","DOI":"10.5152\/eurasianjmed.2023.23335","article-title":"Factors associated with relapses in alcohol and substance use disorder","volume":"55","author":"Yazici","year":"2023","journal-title":"Eurasian J Med"},{"issue":"3","key":"2026081219562927000_dgag110-B21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J Pers Assess"},{"issue":"10","key":"2026081219562927000_dgag110-B22","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"6","key":"2026081219562927000_dgag110-B23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"6","key":"2026081219562927000_dgag110-B24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2026081219562927000_dgag110-B25","volume-title":"SF-36 Physical and Mental Health Summary Scales: A User's Manual","author":"Ware","year":"1994"},{"issue":"4","key":"2026081219562927000_dgag110-B26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/pubmed\/21.4.372","article-title":"Comparison of UK and US methods for weighting and scoring the SF-36 summary measures","volume":"21","author":"Jenkinson","year":"1999","journal-title":"J Public Health Med"},{"key":"2026081219562927000_dgag110-B27","author":"EKF-Diagnostics"},{"key":"2026081219562927000_dgag110-B28","author":"Schaffert"},{"key":"2026081219562927000_dgag110-B29","author":"World Anti-Doping Agency"},{"key":"2026081219562927000_dgag110-B30","author":"World Anti-Doping Agency"},{"key":"2026081219562927000_dgag110-B31","doi-asserted-by":"crossref","unstructured":"Grant B, Kean J, de Silva NL, et al \u00a0Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study - Supplemental Material. Zenodo. 2026. 10.5281\/zenodo.18817260","DOI":"10.1210\/clinem\/dgag110"},{"issue":"1","key":"2026081219562927000_dgag110-B32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.15187","article-title":"Androgen abuse: risks and adverse effects in men","volume":"1538","author":"Grant","year":"2024","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2026081219562927000_dgag110-B33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1521-0391.2013.12118.x","article-title":"The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates","volume":"23","author":"Pope","year":"2014","journal-title":"Am J Addict"},{"issue":"12","key":"2026081219562927000_dgag110-B34","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1360-0443.2009.02734.x","article-title":"Anabolic-androgenic steroid dependence: an emerging disorder","volume":"104","author":"Kanayama","year":"2009","journal-title":"Addiction"},{"issue":"6","key":"2026081219562927000_dgag110-B35","doi-asserted-by":"crossref","first-page":"1557988320966536","DOI":"10.1177\/1557988320966536","article-title":"Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men","volume":"14","author":"Bonnecaze","year":"2020","journal-title":"Am J Mens Health"},{"key":"2026081219562927000_dgag110-B36","author":"Office for Life Sciences"},{"key":"2026081219562927000_dgag110-B37","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.etdah.2022.100033","article-title":"Two sides of the same coin: a qualitative exploration of experiential and perceptual factors which influence the clinical interaction between physicians and anabolic-androgenic steroid using patients in the UK","volume":"2","author":"Ainsworth","year":"2022","journal-title":"Emerg Trends Drugs Addict Health"},{"issue":"2","key":"2026081219562927000_dgag110-B38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2265.2012.04486.x","article-title":"Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism","volume":"78","author":"Caronia","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026081219562927000_dgag110-B39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0039-128X(73)90110-4","article-title":"Diurnal variations of plasma testosterone in men","volume":"22","author":"Barberia","year":"1973","journal-title":"Steroids"},{"issue":"1","key":"2026081219562927000_dgag110-B40","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1186\/s12889-022-13734-4","article-title":"Fake anabolic androgenic steroids on the black market - a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature","volume":"22","author":"Magnolini","year":"2022","journal-title":"BMC Public Health"},{"issue":"2","key":"2026081219562927000_dgag110-B41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/jat\/24.2.102","article-title":"Evaluation of testosterone\/epitestosterone ratio influential factors as determined in doping analysis","volume":"24","author":"van de Kerkhof","year":"2000","journal-title":"J Anal Toxicol"},{"issue":"12","key":"2026081219562927000_dgag110-B42","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1507\/endocrj.EJ12-0134","article-title":"Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions","volume":"59","author":"Aydogan","year":"2012","journal-title":"Endocr J"},{"issue":"8","key":"2026081219562927000_dgag110-B43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1176\/appi.ajp.157.8.1291","article-title":"Muscle dysmorphia in male weightlifters: a case-control study","volume":"157","author":"Olivardia","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2026081219562927000_dgag110-B44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0033-3182(97)71400-2","article-title":"Muscle dysmorphia. An underrecognized form of body dysmorphic disorder","volume":"38","author":"Pope","year":"1997","journal-title":"Psychosomatics"},{"key":"2026081219562927000_dgag110-B45","doi-asserted-by":"crossref","first-page":"109121","DOI":"10.1016\/j.steroids.2022.109121","article-title":"Association between neuronal degeneration and supraphysiological doses of two types of anabolic steroids in rat brain","volume":"188","author":"Corsini","year":"2022","journal-title":"Steroids"},{"issue":"5","key":"2026081219562927000_dgag110-B46","first-page":"579","article-title":"Long-term anabolic\u2013androgenic steroid use is associated with deviant brain aging","volume":"6","author":"Bj\u00f8rnebekk","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"1","key":"2026081219562927000_dgag110-B47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000012362","article-title":"Psychiatric and medical effects of anabolic-androgenic steroid use in women","volume":"69","author":"Gruber","year":"2000","journal-title":"Psychother Psychosom"},{"issue":"9","key":"2026081219562927000_dgag110-B48","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jsams.2017.03.008","article-title":"Somatic effects of AAS abuse: a 30-years follow-up study of male former power sports athletes","volume":"20","author":"Lindqvist Bagge","year":"2017","journal-title":"J Sci Med Sport"},{"issue":"5","key":"2026081219562927000_dgag110-B49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/dar.12688","article-title":"Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolic-androgenic steroid users","volume":"37","author":"Griffiths","year":"2018","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"2026081219562927000_dgag110-B50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1176\/appi.ajp.2009.08111699","article-title":"Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence","volume":"166","author":"Kanayama","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2026081219562927000_dgag110-B51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-0102(96)01141-8","article-title":"Anabolic androgenic steroids increase \u03b2-endorphin levels in the ventral tegmental area in the male rat brain","volume":"27","author":"Johansson","year":"1997","journal-title":"Neurosci Res"},{"issue":"2","key":"2026081219562927000_dgag110-B52","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.npep.2008.12.005","article-title":"Nandrolone decanoate administration dose-dependently affects the density of kappa opioid peptide receptors in the rat brain determined by autoradiography","volume":"43","author":"Magnusson","year":"2009","journal-title":"Neuropeptides"},{"key":"2026081219562927000_dgag110-B53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drugalcdep.2015.04.023","article-title":"Brain and cognition abnormalities in long-term anabolic-androgenic steroid users","volume":"152","author":"Kaufman","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2026081219562927000_dgag110-B54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nicl.2016.11.014","article-title":"Brain connectivity aberrations in anabolic-androgenic steroid users","volume":"13","author":"Westlye","year":"2017","journal-title":"Neuroimage Clin"},{"issue":"2","key":"2026081219562927000_dgag110-B55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/sms.13843","article-title":"Positive and negative side effects of androgen abuse. The HAARLEM study: a one-year prospective cohort study in 100 men","volume":"31","author":"Smit","year":"2021","journal-title":"Scand J Med Sci Sports"},{"issue":"7","key":"2026081219562927000_dgag110-B56","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1210\/clinem\/dgae026","article-title":"Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy","volume":"109","author":"Bhasin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026081219562927000_dgag110-B57","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2026081219562927000_dgag110-B58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"2026081219562927000_dgag110-B59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5534\/wjmh.210021","article-title":"Consequences of anabolic-androgenic steroid abuse in males; sexual and reproductive perspective","volume":"40","author":"Corona","year":"2022","journal-title":"World J Mens Health"},{"issue":"3","key":"2026081219562927000_dgag110-B60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/09687637.2021.1882940","article-title":"Libido as a motivator for starting and restarting non-prescribed anabolic androgenic steroid use among men: a mixed-methods study","volume":"29","author":"Harvey","year":"2022","journal-title":"Drugs Educ Prev Policy"},{"issue":"7","key":"2026081219562927000_dgag110-B61","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1210\/jc.2007-1972","article-title":"Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study","volume":"93","author":"Wu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081219562927000_dgag110-B62","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.beem.2022.101622","article-title":"Ageing male (part I): pathophysiology and diagnosis of functional hypogonadism","volume":"36","author":"Huhtaniemi","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"2026081219562927000_dgag110-B63","doi-asserted-by":"crossref","first-page":"e3709","DOI":"10.1210\/clinem\/dgaf157","article-title":"Characterization of leydig cell dysfunction in previous illicit androgen users","volume":"110","author":"Bulut","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag110\/67319019\/dgag110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag110\/67319019\/dgag110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag110\/67319019\/dgag110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:56:38Z","timestamp":1786578998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/9\/2649\/8516682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag110","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,3,12]]}}}